WALTHAM, Mass.--(BUSINESS WIRE)-- Asahi Kasei Pharma America Corp. (AKP America) today announced the initiation of an 800-patient Phase 3 clinical trial for ART-123 (recombinant human thrombomodulin, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results